A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors.
Cancer(2023)
摘要
NCT03507543.
更多查看译文
关键词
Australia,BRCA mutation,PARP inhibitor,recommended phase 2 dose,senaparib,solid tumors
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要